We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » KV Gets Double the Bad News in Ritalin Suit
KV Gets Double the Bad News in Ritalin Suit
August 5, 2008
KV Pharmaceutical lost its counsel when a New Jersey court disqualified the drugmaker’s law firm due to conflict of interest in a patent case against Celgene involving long-acting (LA) Ritalin, a treatment for attention deficit hyperactivity disorder.